Appointment

RNS Number:4027J
Genetix Group PLC
31 March 2003

                   Appointment of VP of North American Sales



New Milton UK, 31 March 2003 - Genetix Group plc (LSE:GTX), the genomics and
proteomics technology group, today announced that it has appointed Jim Bull as
Head of North American Sales. Mr. Bull has 25 years experience of selling
products and services within the life sciences industry.



Most recently Mr. Bull was Director of Sales at GeneMachines where he was
responsible for worldwide sales, helping to make it a key player in its niche
markets.



From 1991-1999, Mr. Bull held sales and marketing positions at Molecular
Dynamics (later Amersham Pharmacia Biotech), including Product Manager and
Director of North American Sales, where he was responsible for sales of
scanners, microarray systems, and automated sequencers, as well as the
successful launch of the MegaBACE DNA sequencing system.



Mr. Bull has also worked as a sales manager for Beckman Instruments and Allergan
Pharmaceuticals.  He is a graduate of Miami University, Oxford OH, where he
studied business administration and marketing.



Mark Reid, Chief Executive Officer of Genetix, said: "The US market already
accounts for 52% of sales and Genetix is committed to strengthening our US
presence further.  We opened our US headquarters in Boston last year and plan
further appointments to boost the US team over coming months.  Jim has
invaluable experience and contacts and a broad knowledge of the market dynamics
within our sector, we are delighted to welcome him to the company."





Enquires:

Genetix Group plc
Mark Reid, Chief Executive Officer                   Tel:  [phone]
Gary Corsi, Finance Director



Financial Dynamics
Jonathan Birt / Francetta Carr                       Tel:  [phone]





Notes to Editors

Genetix Group plc

Genetix Group plc is leading developer of automated systems for the
understanding of systems biology. Genetix made a significant contribution to the
Human Genome Project by supplying high-throughput equipment to seven of the
leading eight laboratories in the consortia. Genetix through its R&D expertise
and scientific resource, is committed to the continual development of innovative
solutions to accelerate the rate of global scientific discovery. Genetix is
quoted on the London Stock Exchange and is based in New Milton, Hampshire, UK.
www.genetix.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCWUUWPWUPWGUG